Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
New research on acute myeloid leukemia from Xi'an Jiao Tong University summarized
April 27th, 2008
"As sensitization of leukemic cells with granulocyte colony-stimulating factor (G-csf) can enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML), a pilot study was conducted in order to evaluate the effect of G-csf priming combined with low-dose chemotherapy in patients with relapsed and refractory AML. The regimen, G-HA, consisted of cytarabine 7.5 mg/m(2)/12 hr by subcutaneous injection, days 1-14, homoharringtonine 1.5 mg/m(2)/day by intravenous continuous infusion, days 1-14, and G-csf 150 mu g/m(2)/day by subcutaneous injection, days 0-14," scientists in Xian, People's Republic of China report. "Thirty-six AML patients were enrolled, 23...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-27)
|
